Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029)

Inclusion Criteria: * Willing and able to provide written informed consent for trial P06029 as well as for the Frozen-Thawed Embryo Transfer (FTET) follow-up trial P06031, and for the pharmacogenetic analysis (if applicable). * Female and \>=35 to \<=42 years of age with indication for COS and IVF/ICSI. * Body weight ≥50.0 kg, body mass index (BMI) \>=18.0 to \<=32.0 kg/m2. * Regular spontaneous menstrual cycle with variation not outside the 24-35 days. * Ejaculatory sperm must be available (donated and/or cryopreserved sperm is allowed). * Results of clinical laboratory tests, cervical smear, physical examination within normal limits or clinically acceptable to the investigator. * Adhere to trial schedule. Exclusion Criteria: * A recent history of/or any current endocrine abnormality. * A history of ovarian hyper-response or ovarian hyperstimulation syndrome (OHSS). * A history of/or current polycystic ovary syndrome. * More than 20 basal antral follicles \<11 mm (both ovaries combined) in the early follicular phase. * Less than 2 ovaries or any other ovarian abnormality. * Unilateral or bilateral hydrosalpinx. * Intrauterine fibroids ≥5 cm or any clinically relevant pathology, which could impair embryo implantation or pregnancy continuation. * More than three unsuccessful COS cycles for IVF/ICSI since the last established ongoing pregnancy (if applicable). * A history of non- or low ovarian response to FSH/human menopausal gonadotropin (hMG) treatment. * A history of recurrent miscarriage. * FSH \>15.0 IU/L or luteinizing hormone (LH) \>12.0 IU/L during the early follicular phase. * Positive for human immunodeficiency virus (HIV) or Hepatitis B. * Contraindications for the use of gonadotropins or gonadotropin releasing hormone (GnRH) antagonists. * A recent history of/or current epilepsy, thrombophilia, diabetes, cardiovascular, gastro-intestinal, hepatic, renal or pulmonary or auto-immune disease requiring regular treatment. * Smoking or recently stopped smoking (ie, within the last 3 months prior to signing informed consent). * A recent history or presence of alcohol or drug abuse. * The participant or the sperm donor has known gene defects, genetic abnormalities, or abnormal karyotyping, relevant for the current indication or for the health of the offspring. * Prior or concomitant medications disallowed by protocol.